Table 1. Patients' demographics.
| RP group (n = 86) | EBRT group (n = 76) | P-value | |
|---|---|---|---|
| Age (mean, years) | 64.9 ± 6.4 | 71.1 ± 5.3 | <0.001 |
| PSA (median, ng mL−1 [range]) | |||
| 8.5 (2.3–268.2) | 14.0 (3.3–205) | 0.020 | |
| Gleason score (n [%]) | 0.067 | ||
| ≤ 6 | 47 (54.6) | 26 (34.2) | |
| 7 | 24 (27.9) | 25 (32.9) | |
| ≥ 8 | 14 (16.3) | 19 (25.0) | |
| Unknown | 1 (1.2) | 6 (7.9) | |
| Clinical T stage (n [%]) | 0.013 | ||
| CT2 | 81 (94.2) | 62 (91.6) | |
| CT3 | 5 (5.8) | 14 (18.4) | |
| Risk subgroup (n [%]) | < 0.001 | ||
| Low | 36 (41.9) | 12 (15.8) | |
| Intermediate | 26 (30.2) | 27 (35.5) | |
| High | 24 (27.9) | 37 (48.7) | |
Abbreviations: RP, radical prostatectomy; EBRT, external beam radiation therapy; PSA, prostate-specific antigen.